Ketchum shuffles its London practice

Share this article:
Ketchum reorganized its London management, naming former European healthcare head Avril Lee as co-deputy CEO, responsible for the office's three main consultancy offers in healthcare, consumer and corporate affairs. She will share the role with Nick Propper.

Susannah Knox moves from director, healthcare to managing director, assuming Lee's previous responsibilities for management and development of the London team serving UK and international clients. Sebastien Desprez becomes managing director of international healthcare.

“There is no question that Susannah and Sebastien have been big forces behind Ketchum's emergence as a London healthcare powerhouse, and we want to give them plenty of room for navigation,” said London CEO David Gallagher. “These new roles will let them deepen and expand the services we're able to offer clients in this sector.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...